IKNA

Ikena Oncology, Inc. [IKNA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IKNA Stock Summary

Top 10 Correlated ETFs

IKNA

Top 10 Correlated Stocks

IKNA

In the News

IKNA Financial details

Company Rating
-
Market Cap
64.18M
Income
-66.87M
Revenue
9.16M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
43
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.4
Forward P/E
-
PEG
1.12
P/S
6.74
P/B
0.55
P/C
-
P/FCF
-1.24
Quick Ratio
10.22
Current Ratio
10.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.61
EPS next Y
-
EPS next Q
-
EPS this Y
-11.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
28.24%
Revenue last 5Y
-7.81%
Revenue Q/Q
-44.39%
EPS Q/Q
2.5%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-28%
ROE
-41%
ROC
-0.35%
Gross Margin
100%
Oper. Margin
-492%
Profit Margin
-433%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.02-7.64
52W High
-80%
52W Low
+40%
RSI
38
Rel Volume
0.18
Avg Volume
429.16K
Volume
77.17K
Perf Week
-4.11%
Perf Month
-12.5%
Perf Quarter
-17.16%
Perf Half Y
-18.13%
-
-
-
-
Beta
0.332
-
-
Volatility
0.04%, 0.04%
Prev Close
-3.45%
Price
1.4
Change
-3.45%

Something similar

Top by Market Cap
VTSAX
TSLA
AMZ.DE
JPM
GOOG
Top Correlated ETFs
KCCA
HDRO
RNRG
Top Correlated Stocks
FLGT
3939.T
MNST
NKTR
PBYI
Similar Market Cap
SPR.L
9998.HK
BOREO.HE
8036.HK
PLBBX

Company Profile

Healthcare Biotechnology
  • Volume Average 429.16K
  • Market Capitalization 64.18M
  • Employee 43
  • CEO Dr. Mark Manfredi Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2021-03-26
  • Website https://ikenaoncology.com

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.